Population: Immunocompromised host

An individual with an impaired immune system due to conditions such as HIV, cancer, organ transplantation, or immunosuppressive therapy

Pinargote-Celorio

Spain
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Sotrovimab

Nguyen

France
|
2021-2022
  • Adults (18-64 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Tixagevimab/Cilgavimab

Rinaldi

Italy
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Molnupiravir

COCOPREV

France
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Basoulis

Greece
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Remdesivir

Schlosser

Germany
|
2022
  • Fragile population
  • Immunocompromised host
  • SARS-CoV-2
  • Post-COVID-19

PISCIS

Spain
|
2022-2022
  • Adults (18-64 years)
  • Fragile population
  • People at high risk of STIs
  • Immunocompromised host
  • PrEP users
  • People living with HIV
  • Non-hospital health centre
  • Telemedicine
  • Monkeypox virus
  • Mpox
  • Pharmacological intervention
  • Vaccination

NOVELLA

Russian Federation
|
2023-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • AZD3152/Sipavibart

MonVIP

France
|
2023
  • Adults (18-64 years)
  • Fragile population
  • People at high risk of STIs
  • Immunocompromised host
  • PrEP users
  • People living with HIV
  • Hospital
  • Outpatient clinic
  • Infectious diseases unit
  • Monkeypox virus
  • Mpox

MASH-1

United Kingdom France Spain Poland
|
2024-2024
  • Adults (18-64 years)
  • Fragile population
  • People at high risk of STIs
  • Immunocompromised host
  • PrEP users
  • People living with HIV
  • Outpatient clinic
  • Non-hospital health centre
  • STD/STI clinic
  • Monkeypox virus
  • Mpox

Kowalski

Poland
|
2022-2022
  • Adults (18-64 years)
  • Fragile population
  • People at high risk of STIs
  • Immunocompromised host
  • Men who have sex with men
  • People living with HIV
  • Hospital
  • Monkeypox virus
  • Mpox

Gotz

Germany
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19